Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications (Q37893536)

24 August 2017

1 reference

title

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications (English)

1 reference

attention deficit hyperactivity disorder

24 August 2017

0 references

adult attention deficit hyperactivity disorder

1 reference

Paul G Hammerness

1

1 reference

24 August 2017

Craig B H Surman

series ordinal

2

1 reference

24 August 2017

Ashley Chilton

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Current Psychiatry Reports

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

5

1 reference

24 August 2017

357-363

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-011-0213-3

24 August 2017

0 references

cites work

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Review of medication adherence in children and adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Atomoxetine treatment for ADHD: younger adults compared with older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Effect of atomoxetine on executive function impairments in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Cardiovascular effects of atomoxetine in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

ADHD drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Resting heart rate in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

A Randomized, Single-Blind, Substitution Study of OROS Methylphenidate (Concerta) in ADHD Adults Receiving Immediate Release Methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-011-0213-3

Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.

21 January 2018

1 reference

12 December 2020

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

1 reference

12 December 2020

The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm

1 reference

12 December 2020

Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD

1 reference

12 December 2020

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

1 reference

12 December 2020

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.

1 reference

12 December 2020

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

10.1007/S11920-011-0213-3

Identifiers

DOI

1 reference

24 August 2017

1 reference